<DOC>
	<DOC>NCT00608868</DOC>
	<brief_summary>The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor.</brief_summary>
	<brief_title>SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathological Diagnosis of local advanced/metastatic Non Small Cell Lung Carcinoma Previously failed the firstline chemotherapy Patient who can provide sample for EGFR mutation test Central Nervous System metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation Any evidence of clinically active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Non Small Cell Lung</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Gefitinib</keyword>
</DOC>